Bluejay Diagnostics, Inc. (BJDX)
- Previous Close
0.1429 - Open
0.1390 - Bid --
- Ask --
- Day's Range
0.1353 - 0.1440 - 52 Week Range
0.1310 - 48.8000 - Volume
419,155 - Avg. Volume
2,123,814 - Market Cap (intraday)
2.381M - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-43.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
256.00
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
bluejaydx.comRecent News: BJDX
View MorePerformance Overview: BJDX
Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BJDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BJDX
View MoreValuation Measures
Market Cap
2.36M
Enterprise Value
-5.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.51%
Return on Equity (ttm)
-125.25%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.4M
Diluted EPS (ttm)
-43.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
8.06M
Total Debt/Equity (mrq)
5.12%
Levered Free Cash Flow (ttm)
-5.49M